PT Garuda Indonesia's balance sheet deteriorated sharply in the months following a $1.4 billion rescue injection from Indonesia's sovereign wealth fund Danantara in late 2025, as jet fuel cost escalation negated the capital infusion and triggered an equity crisis.
Shareholder approval for the rescue measures was secured on Nov. 12, 2025. The fund provided the largest single capital injection in Garuda's history, intended to support a long-delayed turnaround.
Instead, the airline reported a $323 million loss despite the infusion. Rising operational costs and weaker revenue compressed margins, but fuel costs drove the deterioration. The war in Iran added substantial cost pressure to jet fuel markets, eroding what had been a narrowing path to recovery.
Garuda had previously grounded 40 percent of its fleet in cost-containment efforts. The mothballed aircraft continued incurring carrying costs the airline could not absorb.
The financial damage was swift. In June, the airline had projected a $65 million deficit by year-end. By late 2025, management shifted guidance to an expected $183 million swing from losses to positive equity—a modest recovery that proved illusory as fuel prices continued climbing.
The Danantara injection proved insufficient to offset the sustained cost increases, forcing management to accelerate a planned equity raise to stabilize liabilities. Full-year financial results are due in March and will provide the first comprehensive picture of the rescue plan's efficacy against persistent commodity headwinds.
Garuda's structural vulnerability—high fuel intensity, aging fleet, and limited pricing power in competitive regional markets—remains unresolved by capital injection alone. The equity crisis underscores why global carriers operating on thin margins face existential risk during volatile commodity cycles.
